查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961287

Xa因子抑制劑市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、給藥途徑、應用、地區和競爭格局分類，2021-2031年

Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 Xa 因子抑制劑市場預計將從 2025 年的 234.6 億美元成長到 2031 年的 331.3 億美元，複合年成長率為 5.92%。

凝血因子Xa是一種關鍵的絲胺酸蛋白酶，在凝血級聯反應中負責合成凝血酶，是直介面服抗凝血劑（DOACs）的作用標靶，旨在預防和治療血栓性栓塞症。該領域的發展主要受全球老年人口成長以及臨床治療從維生素K拮抗劑轉向直接凝血因子Xa抑制劑的驅動。直接凝血因子Xa抑制劑因其更高的安全性以及便捷的固定劑量方案（可提高患者的用藥依從性）而備受關注。

市場概覽
預測期 2027-2031
市場規模：2025年 234.6億美元
市場規模：2031年 331.3億美元
複合年成長率：2026-2031年 5.92%
成長最快的細分市場 肺動脈栓塞
最大的市場 北美洲

然而，出血不良事件的顯著風險阻礙了市場發展，使治療策略複雜化，並需要昂貴的逆轉治療。儘管存在這些障礙，凝血障礙在全球範圍內造成的嚴重影響仍然凸顯了對這些治療方法的根本需求。根據國際血栓與止血學會（ISTH）的預測，到2024年，全球四分之一的死亡將由血栓症形成引起，這凸顯了即使存在相關臨床風險，對有效抗凝血治療的迫切需求依然存在。

市場促進因素

全球血栓性栓塞症和心血管疾病盛行率的上升是Xa因子抑制劑市場成長的主要促進因素。中風和靜脈血栓栓塞症發病率的增加推動了臨床對直接作用Xa因子抑制劑作為標準預防性治療的需求。這種沉重的疾病負擔也反映在死亡率統計數據中；根據美國心臟協會（AHA）於2024年1月發布的《2024年心血管疾病和中風統計數據》，2021年全球約有1991萬人死於心血管疾病。如此廣泛的發病率正轉化為主要行業參與者的可觀收入。百時美施貴寶公司於2024年2月發布的《2023會計年度第四季及全年報告》顯示，其艾樂妥（Eliquis）的全球銷售額達到122億美元，進一步證明了此類藥物龐大的商業性規模。

同時，需要抗凝血治療的老年人口迅速成長，推動了市場擴張。老齡化是心房顫動的主要危險因素，而長期抑制Xa因子是預防中風的必要措施。隨著全球平均壽命的延長，符合治療條件的患者數量成長速度超過了先前的預測。加州大學舊金山分校於2024年9月在《美國心臟病學會雜誌》上發表的一項研究表明，新的數據顯示，美國將有1050萬成年人受到心房顫動的影響，是先前估計的三倍。這一人口趨勢必然導致患者群體擴大，而Xa因子抑制劑在老年人群中具有固定劑量和卓越的安全性，這促使醫療保健提供者優先考慮使用此類藥物。

市場挑戰

出血不良事件的風險是全球Xa因子抑制劑市場成長的主要障礙。口服抗凝血劑雖然對預防中風至關重要，但其可能導致嚴重出血，包括顱內出血和消化道出血，這引起了醫療專業人員的極大關注。這些安全問題需要嚴格的患者篩選和監測通訊協定，從而阻礙了市場發展，削弱了固定劑量給藥方案的便利性。此外，治療這些併發症和使用某些逆轉劑的高昂費用也導致醫生在處方方面猶豫不決，尤其是在醫療預算緊張的地區。

近期安全性數據凸顯了這項臨床挑戰的嚴峻性。根據美國心臟協會 (AHA) 2024 年的報告，臨床研究顯示，在接受某些 Xa 因子抑制劑治療的患者中，每 100 人年發生約 4.9 例大出血事件。這項統計數據強調了抗凝血治療固有的不穩定性，並支持謹慎的處方策略，儘管凝血障礙十分普遍，但這種策略限制了市場的潛在成長。

市場趨勢

隨著主要藥物專利到期，學名藥的湧現正在從根本上改變Xa因子抑制劑市場。轉向更經濟實惠的替代藥物降低了抗凝血治療的經濟門檻，並在預算緊張的醫療保健系統中擴大了患者的用藥途徑。近期生物等效替代藥物的監管核准進一步凸顯了這一趨勢的強勁勢頭。正如《管理式醫療保健執行官》（Managed Healthcare Executive）2025年3月刊報導的《FDA核准首個非專利Xarelto》，美國食品藥物管理局（FDA）核准了Lupin和Taro Pharmaceuticals等公司生產的首批2.5毫克Rivaroxaban藥片學名藥藥。這標誌著該治療領域定價結構的重大轉變。

同時，某些逆轉劑的商業化緩解了一個重要的安全隱患：與Xa因子抑制相關的無法控制的出血。諸如安德沙奈特α（andexanet alfa）等解毒劑的廣泛應用，為臨床醫生提供了一種可靠的策略來應對危及生命的緊急情況，並增強了他們對處方直介面服抗凝劑而非維生素K拮抗劑的信心。關鍵逆轉劑的財務成功也印證了這種對安全性治療方法的需求。根據Astra Zeneca於2025年2月發布的2024會計年度年度報告和20-F表格資訊，其逆轉劑安德沙奈特α的全球銷售額成長了20%，達到2.19億美元，表明這些藥物正迅速被納入標準急救醫療通訊協定。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Xa因子抑制劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（直接Xa因子抑制劑、間接Xa因子抑制劑）
    • 給藥途徑（口服、注射）
    • 適應症（心房顫動、深層靜脈栓塞症、肺動脈栓塞等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美Xa因子抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲Xa因子抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區Xa因子抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲地區Xa因子抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美因子Xa抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球Xa因子抑制劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27608

The Global Factor Xa Inhibitors Market is projected to expand from USD 23.46 Billion in 2025 to USD 33.13 Billion by 2031, reflecting a compound annual growth rate of 5.92%. Factor Xa, a critical serine protease enzyme in the coagulation cascade that synthesizes thrombin, is the target for direct oral anticoagulants (DOACs) designed to prevent and treat thromboembolic conditions. Growth in this sector is largely fueled by a rising global geriatric population and a significant clinical shift away from vitamin K antagonists toward direct Factor Xa inhibitors, which are favored for their enhanced safety profiles and convenient fixed dosing regimens that improve patient compliance.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 23.46 Billion
Market Size 2031USD 33.13 Billion
CAGR 2026-20315.92%
Fastest Growing SegmentPulmonary Embolism
Largest MarketNorth America

However, market advancement is hindered by the significant risk of adverse bleeding events, which complicates treatment strategies and necessitates expensive reversal agents. Despite this obstacle, the profound global impact of clotting disorders sustains underlying demand for these therapies. According to the International Society on Thrombosis and Haemostasis, thrombosis caused one in four deaths globally in 2024, highlighting the critical and ongoing need for effective anticoagulant treatments even amidst the associated clinical risks.

Market Driver

The rising global prevalence of thromboembolic and cardiovascular diseases acts as the primary engine for the Factor Xa Inhibitors Market's growth. With increasing rates of stroke and venous thromboembolism, the clinical demand for direct Factor Xa inhibitors as the standard preventative care has intensified. This heavy disease burden is reflected in mortality statistics; according to the American Heart Association's "Heart Disease and Stroke Statistics-2024 Update" from January 2024, cardiovascular disease caused roughly 19.91 million deaths worldwide in 2021. Such widespread prevalence translates into substantial revenue for major industry players, as evidenced by Bristol Myers Squibb's "Fourth Quarter and Full-Year Financial Results for 2023" report in February 2024, which announced $12.2 billion in global revenue for Eliquis, confirming the immense commercial magnitude of this drug class.

Concurrently, the rapid expansion of the aging population requiring anticoagulation therapy is boosting market development. Aging is a key risk factor for atrial fibrillation, a condition demanding chronic Factor Xa inhibition to prevent strokes. As global life expectancy increases, the number of eligible patients is surpassing previous estimates. According to a study published by the University of California San Francisco in the "Journal of the American College of Cardiology" in September 2024, new data suggests atrial fibrillation now impacts 10.5 million adults in the United States, a figure triple that of earlier projections. This demographic trend guarantees a widening patient base, urging healthcare providers to favor Factor Xa inhibitors due to their fixed dosing and superior safety profiles for older adults.

Market Challenge

The danger of adverse bleeding events serves as a major obstacle to the growth of the Global Factor Xa Inhibitors Market. Although direct oral anticoagulants are vital for stroke prevention, the possibility of severe hemorrhages, including intracranial or gastrointestinal bleeding, generates significant concern among medical professionals. These safety issues impede market progress by requiring strict patient selection and monitoring protocols, which diminish the convenience offered by fixed dosing schedules. Additionally, the high costs associated with managing these complications and utilizing specific reversal agents lead to prescribing hesitation, particularly in healthcare regions with strict budget constraints.

Recent safety data highlights the severity of this clinical challenge. According to the American Heart Association in 2024, clinical studies revealed that the incidence of major bleeding events in patients receiving specific Factor Xa inhibitors was approximately 4.9 per 100 person-years. This statistical proof emphasizes the inherent volatility of anticoagulant therapy, supporting a cautious prescribing approach that limits the market's potential growth trajectory despite the widespread prevalence of clotting disorders.

Market Trends

The introduction of generic formulations, spurred by recent patent expirations for major drugs, is fundamentally transforming the Factor Xa inhibitors sector. This shift toward more affordable alternatives is lowering the financial obstacles to anticoagulation therapy, thereby broadening patient access within budget-constrained healthcare systems. The strength of this trend is highlighted by recent regulatory approvals for bioequivalent options. As reported by Managed Healthcare Executive in the March 2025 article "FDA Approves First Generics of Xarelto," the U.S. Food and Drug Administration has cleared the first generic versions of rivaroxaban 2.5 mg tablets from manufacturers like Lupin and Taro Pharmaceuticals, signaling a major change in the pricing structure of this therapeutic category.

At the same time, the commercial availability of specific reversal agents is mitigating the critical safety concern of uncontrolled bleeding linked to Factor Xa inhibition. The growing use of antidotes such as andexanet alfa offers clinicians a dependable strategy for handling life-threatening emergencies, thereby bolstering confidence in the prescription of direct oral anticoagulants over vitamin K antagonists. This demand for safety-focused therapies is evident in the financial success of leading reversal agents. According to AstraZeneca's "Annual Report and Form 20-F Information 2024" released in February 2025, worldwide revenue for its reversal agent Andexxa increased by 20% to $219 million, demonstrating the rapid incorporation of these agents into standard emergency care protocols.

Key Market Players

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Daiichi Sankyo Company, Limited
  • Sanofi S.A.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Mylan N.V.

Report Scope

In this report, the Global Factor Xa Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Factor Xa Inhibitors Market, By Drug Type

  • Direct Factor Xa Inhibitors
  • Indirect Factor Xa Inhibitors

Factor Xa Inhibitors Market, By Route of Administration

  • Oral
  • Injectable

Factor Xa Inhibitors Market, By Application

  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Others

Factor Xa Inhibitors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Factor Xa Inhibitors Market.

Available Customizations:

Global Factor Xa Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Factor Xa Inhibitors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Direct Factor Xa Inhibitors, Indirect Factor Xa Inhibitors)
    • 5.2.2. By Route of Administration (Oral, Injectable)
    • 5.2.3. By Application (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Factor Xa Inhibitors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Factor Xa Inhibitors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Factor Xa Inhibitors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Factor Xa Inhibitors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Application

7. Europe Factor Xa Inhibitors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Factor Xa Inhibitors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Application
    • 7.3.2. France Factor Xa Inhibitors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Factor Xa Inhibitors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Factor Xa Inhibitors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Factor Xa Inhibitors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Application

8. Asia Pacific Factor Xa Inhibitors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Factor Xa Inhibitors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Application
    • 8.3.2. India Factor Xa Inhibitors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Factor Xa Inhibitors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Factor Xa Inhibitors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Factor Xa Inhibitors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Application

9. Middle East & Africa Factor Xa Inhibitors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Factor Xa Inhibitors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Factor Xa Inhibitors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Factor Xa Inhibitors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Application

10. South America Factor Xa Inhibitors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Factor Xa Inhibitors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Factor Xa Inhibitors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Factor Xa Inhibitors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Factor Xa Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Teva Pharmaceutical Industries Ltd.
  • 15.3. Bayer AG
  • 15.4. Pfizer Inc.
  • 15.5. Daiichi Sankyo Company, Limited
  • 15.6. Sanofi S.A.
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. GlaxoSmithKline plc
  • 15.9. Dr. Reddy's Laboratories Ltd.
  • 15.10. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer